Seminars in Oncology
Volume 30, Issue 5 , Pages 649-658 , October 2003

Immunotherapy for prostate cancer

  • Lawrence Fong

      Affiliations

    • Departments of Medicine, and Microbiology/Immunology, University of California, San Francisco, San Francisco, CA, USA
    • Corresponding Author InformationAddress reprint requests to Lawrence Fong, MD, UCSF Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94143-1711, USA
    • ,
  • Eric J Small

      Affiliations

    • Departments of Medicine and Urology, University of California, San Francisco, San Francisco, CA, USA

References 

  1. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system (Turning lymphocytes off). Science. 1998;280:243–248
  2. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245–273
  3. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142:1011–1017
  4. Plowman PN, Perry LA, Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol. 1987;59:255–257
  5. Storlie JA, Buckner JC, Wiseman GA, et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995;76:96–100
  6. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428–1434
  7. Small EJ, McMillan A, Meyer M, et al.  Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients (Association with progression-free survival, pain end points, and survival). J Clin Oncol. 2001;19:1304–1311
  8. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031–2040
  9. Slovin SF, Scher HI. Peptide and carbohydrate vaccines in relapsed prostate cancer (Immunogenicity of synthetic vaccines in man—Clinical trials at Memorial Sloan-Kettering Cancer Center). Semin Oncol. 1999;26:448–454
  10. Fong L, Brockstedt D, Benike C, et al.  Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167:7150–7156
  11. Rini BI, Weinberg V, Bok R, et al.  Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99–105
  12. Heiser A, Coleman D, Dannull J, et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409–417
  13. Yamamoto JK, Kruzel ML, Louie H, et al.  Inhibition of human immunodeficiency virus type 1 replication by human interferons alpha, beta and gamma. Arch Immunol Ther Exp. 1993;41:185–191
  14. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 1999;10:485–492
  15. Correale P, Walmsley K, Nieroda C, et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89:293–300
  16. Xue BH, Zhang Y, Sosman JA, et al.  Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate. 1997;30:73–78
  17. Sanda MG, Smith DC, Charles LG, et al.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53:260–266
  18. Eder JP, Kantoff PW, Roper K, et al.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632–1638
  19. Gulley J, Chen AP, Dahut W, et al.  Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53:109–117
  20. Vihko P, Virkkunen P, Henttu P, et al.  Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett. 1988;236:275–281
  21. Fong L, Benike C, Brockstedt D, et al.  Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase administered via different routes induces cellular immune responses in prostate cancer patients. Proc Am Assoc Cancer Res. 1999;40:85; (abstr)
  22. Small EJ, Fratesi P, Reese DM, et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–3903
  23. Small EJ, Rini B, Higano C, et al.  A randomized, placebo-controlled phase III trial of APC8015 (Provenge) in patients with androgen-independent prostate cancer (AiPCa). Proc Am Soc Clin Oncol. 2003;22:382; (abstr)
  24. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002;62:5807–5812
  25. Murphy G, Tjoa B, Ragde H, et al.  Phase I clinical trial (T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen). Prostate. 1996;29:371–380
  26. Murphy GP, Tjoa BA, Simmons SJ, et al.  Phase II prostate cancer vaccine trial (Report of a study involving 37 patients with disease recurrence following primary treatment). Prostate. 1999;39:54–59
  27. Tjoa BA, Simmons SJ, Elgamal A, et al.  Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999;40:125–129
  28. Simons JW, Mikhak B, Chang JF, et al.  Induction of immunity to prostate cancer antigens (Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer). Cancer Res. 1999;59:5160–5168
  29. Mincheff M, Tchakarov S, Zoubak S, et al.  Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer (A phase I/II clinical trial). Eur Urol. 2000;38:208–217
  30. Nair SK, Heiser A, Boczkowski D, et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011–1017
  31. Heiser A, Maurice MA, Yancey DR, et al.  Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–2960
  32. Agus DB, Scher HI, Higgins B, et al.  Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999;59:4761–4764
  33. Reese DM, Small EJ, Magrane G, et al.  HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001;116:234–239
  34. McDevitt MR, Barendswaard E, Ma D, et al.  An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–6100
  35. Fracasso G, Bellisola G, Cingarlini S, et al.  Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate. 2002;53:9–23
  36. Deb N, Goris M, Trisler K, et al.  Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2:1289–1297
  37. Bander NH, Trabulsi EJ, Yao D, et al.  Phase I radioimmunotherapy (RIT) trials of humanized monoclonal antibody (mAb) J591 to the extracellular domain of prostate specific membrane antigen (PSMA ext) radiolabeled with 90 yttrium (90Y) or 177 lutetium (177Lu) in advanced prostate cancer (Pca). Proc Am Soc Clin Oncol. 2002;21:5a; (abstr 18)
  38. Alvarez RD, Partridge EE, Khazaeli MB, et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49 (A phase I/II study). Gynecol Oncol. 1997;65:94–101
  39. Myers RB, Meredith RF, Schlom J, et al.  Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol. 1994;152:243–246
  40. Slovin SF, Scher HI, Divgi CR, et al.  Interferon-gamma and monoclonal antibody 131I-labeled CC49 (Outcomes in patients with androgen-independent prostate cancer). Clin Cancer Res. 1998;4:643–651
  41. Meredith RF, Bueschen AJ, Khazaeli MB, et al.  Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35:1017–1022
  42. Meredith RF, Khazaeli MB, Macey DJ, et al.  Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res. 1999;5(suppl):3254s–3258s
  43. Katzenwadel A, Schleer H, Gierschner D, et al.  Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res. 2000;20:1551–1555
  44. Slovin SF, Ragupathi G, Adluri S, et al.  Carbohydrate vaccines in cancer (Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man). Proc Natl Acad Sci USA. 1999;96:5710–5715
  45. Dranoff G, Jaffee E, Lazenby A, et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543
  46. Baskar S, Glimcher L, Nabavi N, et al.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med. 1995;181:619–629
  47. Simons J, Nelson W, Nemunaitis J, et al.  Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol. 2002;21:183a; (abstr 729)
  48. Small EJ, Reese DM, Um B, et al.  Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:1738–1744
  49. Egen JG, Kuhns MS, Allison JP. CTLA-4 (New insights into its biological function and use in tumor immunotherapy). Nat Immunol. 2002;3:611–618
  50. Hurwitz AA, Foster BA, Kwon ED, et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444–2448
  51. Davis TA, Korman A, Keler T, et al.  MDX-010 (human anti-CTLA4) (A phase 1 trial in hormone refractory prostate carcinoma (HRPC)). Proc Am Soc Clin Oncol. 2002;21:74; (abstr)
  52. Lodge PA, Jones LA, Bader RA, et al.  Dendritic cell-based immunotherapy of prostate cancer (Immune monitoring of a phase II clinical trial). Cancer Res. 2000;60:829–833
  53. Dannull J, Diener PA, Prikler L, et al.  Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000;60:5522–5528
  54. Kiessling A, Schmitz M, Stevanovic S, et al.  Prostate stem cell antigen (Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients). Int J Cancer. 2002;102:390–397
  55. Tsavaler L, Shapero MH, Morkowski S, et al.  Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001;61:3760–3769
  56. Fassò M, Waitz R, Shastri N, et al.  SPAS-1, a novel T cell-defined prostate tumor antigen (Immunological and functional characterization). FASEB J. 2002;16:A667; (abstr)

☆ Supported by by CapCure and NIH NCI Grant No. K23 CA82584-01.

PII: S0093-7754(03)00350-6

doi: 10.1016/S0093-7754(03)00350-6

Seminars in Oncology
Volume 30, Issue 5 , Pages 649-658 , October 2003

Article Tools

* Image Usage & Resolution